Live Chat Support Software
800.227.0627

Nanocarriers for RNA delivery

The extremely short half-lives, poor chemical stability, and natural degradation of RNAs by nucleases resulted in the development of carrier molecules at the nanoscale for RNA delivery into cells. Nanoparticle-based delivery systems protect RNA molecules from enzymatic degradation and immune system attacks and enable the accumulation of RNA in tumors. In general, nanoparticles range from 10 to 200 nanometers (nm), which enhances their tumor permeability and retention effect.

Currently, nanocarriers employed for RNA delivery are

(i)    lipid-based nano-systems,

(ii)   polymeric nanomaterials,

(iii)  inorganic nanoparticles, or

(iv)  Bio-inspired nanovehicles.

Table 1 :  

Nanoparticle-based platforms for RNA delivery (Lin et al. 2020).

Nanocarriers

Classifications

Advantages

Disadvantages

Lipid-based nanostructures

Liposomes;

solid lipid nanoparticles; lipid emulsions

Easy preparation, with good biocompatibility and biodegradability.

Limited stability, easy leakage of payloads, and rapid clearance.

Polymer-based nanomaterials

Natural or naturally derived polymers: chitosan,

poly-l-lysine, atelocollagen, etc.
Synthetic polymers: PLGA, PEI, PVA, PLA, PEG, etc.

Good biocompatibility and biodegradability for natural or naturally derived polymers, low cost of production, stimulation of drug release, easy modification.

Nondegradable for some responsive polymers, dose-dependent toxicity.

Inorganic NPs

MSNs, CNTs, QDs, and metal nanoparticles (e.g., iron oxide and gold nanoparticles)

Easy surface modification, good reproducibility, and easy cell uptake.

Non-biodegradability, potential toxicity.

Bio-inspired nano-vehicles

DNA-based nanostructures,

exosome-mimetic nanovesicles, red blood cell member-based ghosts.

Good biodegradability, low toxicity, strong targeting and low immune induction.

High cost, stability concern.

.

Reference

Lin YX, Wang Y, Blake S, Yu M, Mei L, Wang H, Shi J. RNA Nanotechnology-Mediated Cancer Immunotherapy. Theranostics 2020; 10(1):281-299. doi:10.7150/thno.35568. Available from
http://www.thno.org/v10p0281.htm

 

---...---